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Abstract Resistance to drug treatment is a common observation
in malignant melanoma. In order to analyze alterations in
mRNA expression profiles associated with drug resistance in
melanoma cells we previously established a panel of various drug-
resistant cell variants derived from the human melanoma line
MeWo and compared the mRNA expression profiles by a
differential display technique. By that approach it could be
demonstrated that the expression level of a mRNA encoded by a
gene found to be mutated in non-syndromic hearing impairment,
DFNA5 (ICERE-1), was distinctly decreased in the 33-fold
etoposide-resistant melanoma cell line MeWo ETO 1. To
evaluate the hypothesis that a decrease in DFNA5 mRNA
expression level contributes to the acquired etoposide resistance
phenotype exhibited by MeWo ETO 1 cells, this drug-resistant
line was stably transfected with the DFNA5-encoding cDNA.
Transfected clones showed a 30^35% reduced etoposide suscept-
ibility by comparing the IC25, IC50 and IC75 values of these
clones with those displayed by the non-transfected, etoposide-
resistant melanoma cell line MeWo ETO 1 and controls.
Furthermore, etoposide exposure of stable DFNA5 transfectants
resulted in an increase of caspase-3-mediated apoptotic events in
DFNA5-transfected clones in comparison to MeWo ETO 1 cells
and controls. The data therefore demonstrate that a decrease in
DNFA5 mRNA expression level is associated with an increased
etoposide resistance in melanoma cells due to an elevated cellular
susceptibility to trigger a caspase-3-depending signal pathway
leading to programmed cell death. ß 2001 Federation of Euro-
pean Biochemical Societies. Published by Elsevier Science B.V.
All rights reserved.
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1. Introduction
Resistance to antineoplastic agents is a major obstacle to
successful treatment of metastatic malignant melanoma.
Although moderate response rates of 20^50% of limited du-
ration can be obtained, relapses occur with high frequency
and second-line therapies are largely ine¡ective leading to a
5-year survival rate of 2%. Several mechanisms have been
described mediating drug resistance in cancerous cells, but
in malignant melanoma the processes leading to chemoresis-
tance are largely unknown [1,2]. Consequently, the identi¢ca-
tion of factors involved in the high intrinsic drug resistance of
malignant melanoma is of urgent importance in order to de-
velop new treatment modalities and improve response rates in
advanced melanoma. A signi¢cant correlation between treat-
ment response in melanoma patients and the level of drug
resistance in vitro of fresh single cell suspensions derived
from metastases of these patients was observed [1]. This sug-
gests an important role of cellular mechanisms leading to drug
resistance in melanoma.
In order to get further insights into the mechanisms confer-
ring cellular drug resistance to malignant melanoma, we pre-
viously established a model system in vitro consisting of var-
ious drug-resistant sublines derived from the human
melanoma cell line MeWo [3]. The rationale behind this strat-
egy is the notion that clinically relevant mechanisms of drug
resistance could be de novo induced or could be ampli¢ed in
the case of intrinsic resistance. In that way, the mechanisms
become accessible for detailed and reproducible analysis. This
panel of drug-resistant melanoma cells was analyzed subse-
quently with regard to known mechanisms causing drug resis-
tance in various tissues. In that way, alterations in the activity
of enzyme systems involved in DNA repair [4,5] and of DNA
topoisomerase II [6] could be observed in antitumor drug-re-
sistant melanoma cells. Analyses of changes in the mRNA
expression pro¢les in drug-resistant MeWo derivatives by
the di¡erential display technique [7] revealed various candi-
date factors potentially involved in the drug-resistant pheno-
type [8]. By this approach, a distinct down-regulation of the
mRNA encoding DFNA5 was detected in the MeWo-derived
cell line MeWo ETO 1, characterized by a 33-fold increased
resistance level against the clinically relevant DNA topoiso-
merase II-inhibiting epipodophyllotoxin etoposide.
The human DFNA5 (DFNA is used as the code for dom-
inant hearing impairment genes, and the numerals are as-
signed in order of discovery; overview in [9]) gene encodes a
non-syndromic hearing impairment protein [10] also desig-
nated ICERE-1 [11]. Transcription of the gene revealed a
predicted 496-amino acid protein of unknown physiological
function. Mutations in the DFNA5 gene, resulting in prema-
ture termination of the open reading frame, were found in an
extended family with autosomal dominant deafness [12]. The
expression pattern of DFNA5 indicated that this gene might
participate in the tumor biology of breast cancers [11]. How-
ever, de¢nite proof that DFNA5 is involved in the pathogen-
esis of breast carcinoma is lacking. In addition, a putative role
of DFNA5 in the development of drug resistance in cancer
cells is fully unclear.
To verify the hypothesis that a down-regulation of the
DFNA5-encoding transcript contributes to the development
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of an etoposide resistance phenotype in malignant melanoma
cells, the etoposide-resistant human melanoma cell line MeWo
ETO 1 was transfected with a DFNA5-encoding expression
vector construct. These experiments demonstrated that over-
expression of DFNA5 increased the susceptibility of the drug-
resistant melanoma cell line MeWo ETO 1 to the cytotoxic
action of etoposide mediated by an enhancement of the cel-
lular susceptibility to trigger caspase-3-dependent apoptotic
events.
2. Materials and methods
2.1. Cell lines
Establishment of the etoposide-resistant subline MeWo ETO 1 from
the drug-sensitive human melanoma cell line MeWo [13], derived from
a lymph node metastasis, has been described earlier [3]. Cells were
grown in Leibovitz L-15 medium (Biowhittaker, Walkersville, MD,
USA) supplemented with 10% fetal calf serum (Gibco/BRL, Grand
Island, NY, USA), 1 mM L-glutamine, 6.25 mg/l fetuin, 80 IU/l in-
sulin, 2.5 mg/ml transferrin, 1 g/l glucose, 1.1 g/l NaHCO3, 1% min-
imal essential vitamins, and 20 000 kIU/l trasylol in a humidi¢ed at-
mosphere of 5% CO2 at 37‡C. In order to ensure maintenance of the
etoposide-resistant phenotype, medium for MeWo ETO 1 was supple-
mented with 1.0 Wg/ml etoposide (Bristol-Myers, Munich, Germany).
In addition, the medium used for cultivation of transfected melanoma
cell clones contained 400 Wg/ml G418 (Invitrogen, San Diego, CA,
USA).
2.2. Northern blot analysis
Total RNA was prepared using RNAzol reagent (Gibco/BRL) ac-
cording to the manufacturer’s instructions. 20 Wg of total cellular
RNA was fractionated on 1% agarose-formaldehyde gels and trans-
ferred onto a Hybond-N membrane (Amersham, Aylesbury, UK).
Blots were hybridized with a 635-bp DFNA5-encoding cDNA frag-
ment [8] labeled with [32P]dCTP by random primed labeling (Amer-
sham). Blots were incubated with 25 ng labeled cDNA probe in
6USSPE, 10% dextran sulfate, 7% SDS and 0.5% BLOTTO at
65‡C, for 16 h. Finally, the membrane was washed under high strin-
gency conditions (0.1USSC, 1% SDS at 60‡C). To check that equiv-
alent amounts of RNA were analyzed, the membranes were rehybrid-
ized with a 1.2-kb phosphoglycerate kinase (PGK) cDNA probe.
2.3. Transfection and enforced expression of DFNA5 in MeWo ETO 1
An eukaryotic expression construct containing a full-length
DFNA5-encoding cDNA was kindly provided by D.A. Thompson
(Stanford University School of Medicine, Stanford, CA, USA). The
2168-bp cDNA, designated ICERE-1 [11], was cloned into the EcoRI
(5P-end) and XhoI (3P-end) sites of the mammalian expression vector
pBK-CMV (Stratagene, La Jolla, CA, USA). Sequence analysis was
performed to con¢rm that the insert was in a sense orientation to the
cytomegalovirus (CMV) promoter of the vector. The expression vec-
tor construct was transfected into the etoposide-resistant human mel-
anoma cell line MeWo ETO 1 using liposome transfer (Lipofectin,
Gibco/BRL). Stably transfected cell clones were obtained by using
G418 as selecting agent. As controls, MeWo ETO 1 cells were also
transfected with empty expression vectors.
2.4. Cell growth inhibition assay
Chemoresistance was tested using a cell proliferation assay basing
on sulforhodamine B (SRB), a protein binding reagent [14]. Melano-
ma cells (population doubling time for each cell line including each of
the transfectant clones is 46 h in the absence of any anticancer drug)
were distributed into 96-well plates at a concentration of 5000 cells/
well. For adhesion and to attain logarithmic growth phase cells were
incubated for 48 h prior to drug application. After 6 days chronic
drug incubation the assay was terminated by removing the medium
and adding chilled 10% trichloroacetic acid. After 1 h incubation at
4‡C wells were washed ¢ve times with tap water and cell-associated
protein was stained by adding 0.4% SRB in 1% acetic acid for 10 min
at room temperature. Absorbance was measured at 540 nm after
drying and re-solubilization in 20 mM Tris^HCl (pH 10). For deter-
mination of IC25, IC50 and IC75 values, cells were incubated with
increasing concentrations of etoposide; the absorbance di¡erence of
control cells without drug was set at 100%. Graphs of cell survival
against dose of antineoplastic agent were plotted, and the IC25, IC50
and IC75 values were calculated from multiple (at least three) inde-
pendent experiments for each cell clone.
2.5. Determination of apoptosis
Twenty-four hours prior to chemotherapeutic treatment, cells from
each line were plated into 6-well tissue culture dishes. To induce ap-
optosis, cells were exposed to etoposide for 72 h at 37‡C. For etopo-
side treatment etoposide-resistant melanoma cells MeWo ETO 1, two
independent DFNA5-expressing MeWo ETO 1 clones (MeWo ETO 1/
DFNA5 clone 1 and MeWo ETO 1/DFNA5 clone 2) and a control
clone containing an empty expression vector (MeWo ETO 1/control
clone 1) were either untreated or treated with etoposide 10 or 40
Wg/ml. Sensitive MeWo cells were either unexposed or exposed to
etoposide 1 or 5 Wg/ml, respectively. Live adherent and non-adherent
cells were collected, counted to calculate the survival rate, and used
for the determination of the DNA fragmentation assay. Histone-asso-
ciated DNA fragments released from nuclear fractions of chemother-
apeutically treated cells were quanti¢ed using the Cell Death Detec-
tion ELISA (Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s instructions. DNA fragmentation is presented as
the nucleosome enrichment factor compared to the respective un-
treated control.
2.6. Determination of caspase-3 activity
For the speci¢c quantitative in vitro determination of caspase-3-like
activity a £uorometric immunosorbent enzyme assay (Roche Diagnos-
tics) was used according to the manufacturer’s recommendations.
Brie£y, active caspase-3 was bound by a monoclonal mouse anti-cas-
pase-3 antibody to a microtiter plate. After washing the £uorogenic
caspase-3-speci¢c substrate peptide DEVD-AFC was added and the
caspase-3-catalyzed cleavage rate was measured by £uorescent micro-
plate reader after 1 h with a 409-nm excitation ¢lter and a 500-nm
emission ¢lter. Data were normalized against the untreated control
and interpreted as fold induction. The relative caspase-3 activity val-
ues are means of at least three independent triplicate experiments. The
speci¢city of the assay was con¢rmed using the speci¢c caspase-3-
inhibiting peptide DEVD-CHO (Calbiochem, San Diego, CA, USA)
(data not shown).
3. Results
3.1. Enforced expression of DFNA5-encoding transcripts in
MeWo ETO 1
Since a decreased expression level of DFNA5-encoding
mRNA was detected in the etoposide-resistant melanoma
cell line MeWo ETO 1 [8], a mammalian expression vector
was used to overexpress DFNA5-speci¢c mRNA in a CMV
promoter-dependent manner in this cell line. After G418 se-
lection, several stable DFNA5 cDNA-transfected clones were
obtained. These transfectants demonstrated no gross morpho-
logical changes in comparison to the original cell line MeWo
ETO 1. Starting from these clones, 30 G418-resistant DFNA5
cDNA-transfected clones and 30 G418-resistant control clones
containing an empty expression vector were analyzed for eto-
poside resistance using a SRB-based cell proliferation assay.
Eleven of 30 DFNA5 cDNA-transfected clones showed an
increased sensitivity to etoposide exposure when compared
to the etoposide-resistant cells MeWo ETO 1. None of the
control clones transfected with an empty expression vector
showed any alteration in etoposide sensitivity. Two of the
DFNA5-overexpressing clones (MeWo ETO 1/DFNA5 clone
1 and MeWo ETO 1/DFNA5 clone 2) showing an elevated
etoposide sensitivity were chosen to examine the underlying
mechanisms in more detail. Fig. 1 demonstrates that both
DFNA5 cDNA-transfected clones had an increased DFNA5
mRNA expression level. The extent of DNFA5 expression in
the transfectants was similar to the expression level detected in
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the non-resistant, parental melanoma cell line MeWo. Two
controls, MeWo ETO 1 transfected with an empty expression
vector (MeWo ETO 1/control clone 1) and a DFNA5-trans-
fected MeWo ETO 1 clone (MeWo ETO 1/control clone 2)
exhibiting no modulation in the etoposide-resistant pheno-
type, demonstrated no alteration in DFNA5 mRNA expres-
sion compared to the expression in the non-transfected coun-
terparts.
3.2. Drug sensitivity of DFNA5 cDNA-transfected clones
Examination of etoposide sensitivity of DFNA5 cDNA-
transfected MeWo ETO 1 clones (MeWo ETO 1/DFNA5
clone 1 and MeWo ETO 1/DFNA5 clone 2) revealed a 30^
35% reduced drug susceptibility by comparing the IC50 values
of these clones with the IC50 values exhibited by the non-
transfected, etoposide-resistant melanoma cell line MeWo
ETO 1 and the controls (Fig. 2 and Table 1). The IC25 values
indicating the etoposide resistance of DFNA5 transfectants
were reduced by 54^57% compared to the controls (Table
1). Likewise, at the level of IC75 values, a reduction in etopo-
side sensitivity could be observed in the range of 18^23%
(Table 1).
3.3. Induction of apoptosis by etoposide
Fig. 3 demonstrates that exposure of the non-resistant hu-
man melanoma cell line MeWo to increasing concentrations
of etoposide resulted in an augmentation of apoptotic events
determined by measuring the apoptosis-dependent emergence
Fig. 1. Northern blot analyses of mRNA expression in DFNA5
cDNA-transfected etoposide-resistant melanoma MeWo ETO 1 cell
lines. Total cellular RNA was size-fractionated, transferred to a ny-
lon membrane and hybridized with a 32P-labeled 635-bp DFNA5-
encoding cDNA probe. As control, the blots were probed with a
cDNA encoding PGK. Cells used were: MeWo, non-resistant hu-
man melanoma cell line; MeWo ETO 1, etoposide-resistant deriva-
tive of MeWo; MeWo ETO 1/DFNA5 clone 1, DFNA5 transfected
MeWo ETO 1 clone; MeWo ETO 1/DFNA5 clone 2, DFNA5-
transfected MeWo ETO 1 clone; MeWo ETO 1/control clone 1,
empty vector-transfected MeWo ETO 1 clone; MeWo ETO 1/con-
trol clone 2, DFNA5-transfected MeWo ETO 1 clone showing no
alteration in etoposide resistance.
Fig. 2. Determination of growth inhibition in DFNA5-speci¢c tran-
script-overexpressing melanoma clones after cellular exposure to eto-
poside. Points represent the mean values obtained from at least
three independent experiments. Calculated IC75, IC50 and IC25 val-
ues are given in Table 1.
Table 1
Etoposide sensitivity of DFNA5-overexpressing melanoma clones
Melanoma clone IC75
(Wg/ml)
RRa
(fold)
RSb
(%)
IC50
(Wg/ml)
RR
(fold)
RS
(%)
IC25
(Wg/ml)
RR
(fold)
RS
(%)
MeWo 2.7 þ 0.4 1 3100 1.2 þ 0.2 1 3100 0.27 þ 0.05 1 3100
MeWo ETO 1 70 þ 1 25.9 0 40 þ 1 33.3 0 13 þ 1 48.1 0
MeWo ETO 1/DFNA5 clone 1 54 þ 1 20 322.9 28 þ 1 23.3 330 5.6 þ 0.6 20.7 356.9
MeWo ETO 1/DFNA5 clone 2 58 þ 1 21.5 317.1 26 þ 1 21.7 335 6 þ 0.5 22.2 353.8
MeWo ETO 1/control clone 1 72 þ 1 26.7 +2.8 37 þ 1 30.8 37.5 11 þ 2 40.7 315.4
MeWo ETO 1/control clone 2 67 þ 3 24.9 34.3 44 þ 1 36.7 +10 15 þ 2 55.6 +15.4
aRR, relative resistance (fold) compared to the non-resistant melanoma cell line MeWo.
bRS, relative sensitivity (%) compared to the etoposide-resistant melanoma cell line MeWo ETO 1.
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of mono- and oligonucleosomes in the cytoplasmic fraction of
cell lysates, a 11.6-fold increase using 1 Wg/ml and a 29.9-fold
increase using 5 Wg/ml etoposide. However, etoposide treat-
ment of the etoposide-resistant cell line MeWo ETO 1 did not
lead to such a high programmed cell death rate even using still
higher drug concentrations. Treatment of MeWo ETO 1 cells
with 10 Wg/ml etoposide increased the relative factor of nucleo-
some enrichment by approximately 2.2-fold, whereas exposure
using 40 Wg/ml etoposide increased the quantity of apoptotic
events 2.1-fold. Similar data were obtained using a stably
transfected cell clone with an empty expression vector
(MeWo ETO 1/control clone 1). Etoposide treatment using
10 Wg/ml etoposide resulted in a 1.1-fold increase, exposure
to 40 Wg/ml etoposide led to a 1.7-fold enhancement of nucle-
osomes. In contrast to those non-signi¢cant e¡ects, both sta-
bly DFNA5 cDNA-transfected melanoma clones (MeWo
ETO 1/DFNA5 clone 1 and MeWo ETO 1/DFNA5 clone 2)
demonstrated a much more pronounced increase of apoptotic
events due to etoposide treatment. Etoposide exposure using
10 Wg/ml caused a 2.7-fold (MeWo ETO 1/DFNA5 clone 1) or
2.3-fold (MeWo ETO 1/DFNA5 clone 2) nucleosome en-
hancement, drug exposure using 40 Wg/ml resulted in an
8.5-fold (MeWo ETO 1/DFNA5 clone 1) or an 8.2-fold
(MeWo ETO 1/DFNA5 clone 2) increase of nucleosomes.
3.4. Activation of caspase-3 after etoposide treatment
To de¢ne the apoptotic pathway that is in£uenced by
DFNA5, the catalytic activity of caspase-3 was measured.
Caspase-3 is one death protease, among others, that can be
activated in consequence of an upstream apoptotic signal
transduction and catalyzes the cleavage, and therefore the
breakdown, of several cellular components related to DNA
repair and regulation [15]. The synthetic £uorogenic peptide
DEVD-AFC was used to determine caspase-3-like activity. As
demonstrated in Fig. 4, the caspase-3-mediated cleavage ac-
tivity increased dramatically in drug-sensitive MeWo cells fol-
lowing a 72-h treatment with etoposide (26.5-fold using
1 Wg/ml and 44.7-fold using 5 Wg/ml), while no detectable in-
duction of caspase-3-like activity could be measured in the
etoposide-resistant cell variant MeWo ETO 1 and the empty
expression vector-transfected melanoma cell clone MeWo
ETO 1/control clone 1, even using higher etoposide concen-
trations (40 Wg/ml). In contrast, both DFNA5 cDNA-trans-
fected MeWo ETO 1-derived clones, MeWo ETO 1/DFNA5
clone 1 and clone 2, restored the cellular capability to activate
caspase-3 due to etoposide treatment. Drug exposure using 10
Wg/ml mediated a 1.9-fold (MeWo ETO 1/DFNA5 clone 1) or
2.5-fold (MeWo ETO 1/DFNA5 clone 2) enhancement of the
caspase-3-like catalytic activity, whereas an etoposide concen-
tration of 40 Wg/ml even resulted in a 15.0-fold (MeWo ETO
1/DFNA5 clone 1) or 14.7-fold (MeWo ETO 1/DFNA5 clone
2) increase of caspase-3-mediated peptide cleavage.
4. Discussion
A previously performed evaluation of the mRNA expres-
sion pro¢les in a panel of drug-resistant melanoma cell lines
derived from the MeWo line by the di¡erential display tech-
nique [7] demonstrated that the expression level of the mRNA
encoding a non-syndromic hearing impairment protein,
DNFA5, is distinctly decreased in the etoposide-resistant mel-
anoma cell line MeWo ETO 1 [8]. In this study, we investi-
gated the hypothesis that a decreased expression of the
DFNA5-speci¢c transcript might be involved in the acquired
drug resistance phenotype exhibited by MeWo ETO 1 cells by
a¡ecting the cellular susceptibility to trigger programmed cell
death. Hence, we transfected the etoposide-resistant cell line
MeWo ETO 1 with a CMV promoter-driven DFNA5-encod-
ing cDNA expression vector construct. By this approach it
Fig. 3. Determination of etoposide-dependent induction of apoptosis
in DFNA5 cDNA transfectants as measured by the emergence of
mono- and oligonucleosomes in cytoplasmic fractions of cell lysates
by an ELISA approach. Columns represent the values obtained
from at least three independent experiments, bars represent S.D.
Fig. 4. Activation of caspase-3-like activity in DFNA5 cDNA-trans-
fected MeWo ETO 1 cell variants after exposure to increasing con-
centrations of etoposide. Columns represent the values obtained
from at least three independent experiments, bars represent S.D.
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was possible to enhance the DFNA5 mRNA expression level
to an extent similar to that observed in the original, non-re-
sistant cell line MeWo. DFNA5 mRNA-overexpressing clones
derived from the 33-fold etoposide-resistant melanoma cell
line MeWo ETO 1 showed a 30^35% reduced degree of etopo-
side resistance at the IC50 level compared to non-transfected
MeWo ETO 1 cells and controls assessed by cell proliferation
assays. The fact that approximately one third of DFNA5-
transfected clones and none of the controls reduced their vul-
nerability to etoposide treatment supports the idea that the
new phenotype exhibited by transfected clones is indeed
caused by DFNA5 overexpression and not by unspeci¢c clo-
nal e¡ects.
Sparse data are available concerning the physiological func-
tion of the gene designated DFNA5. At ¢rst, a linkage anal-
ysis identi¢ed this gene as causing hearing loss in an extended
Dutch family with autosomal dominant progressive hearing
loss starting in the high frequencies, and mapped the gene
to chromosome 7p15 [16]. In that family su¡ering from that
type of non-syndromic hearing impairment an insertion/dele-
tion mutation was identi¢ed in intron 7 of the DNFA5 gene
[10]. This mutation causes skipping of exon 8, resulting in
premature termination of the open reading frame. To identify
possible functionally relevant motifs on the basis of the cDNA
and amino acid sequences of human DFNA5 and its murine
counterpart Dfna5h, several databases were searched, but no
signi¢cant results were obtained. Furthermore, no evidence
was provided that Dfna5h is mutated in deaf mouse mutants.
By comparing estrogen receptor (ER)-positive and ER-neg-
ative breast carcinoma cell lines using a di¡erential display
approach the DFNA5- (in that study designated ICERE-1)
encoding mRNA was found to be overexpressed in the ER-
negative breast cancer cell lines [11]. However, alignment of
the original DFNA5 cDNA sequence and the ICERE-1
cDNA sequence revealed two important di¡erences leading
to alternative initiation and stop codons [10]. On the basis
of various considerations, e.g. sequencing of the genomic
DNA prepared from the breast carcinoma cell line MDA-
MB-231 that was used to isolate ICERE-1 cDNA, Van Laer
et al. [10] concluded that DFNA5 and ICERE-1 represent the
same gene and that the start and stop codons had been iden-
ti¢ed incorrectly in ICERE-1. Although it was hypothesized
that DFNA5 may be involved in tumor biology speci¢c to
hormonally unresponsive breast cancers [11], de¢nite proof
is lacking that DFNA5 is involved in the pathogenesis of
breast carcinoma. Nevertheless, since this study revealed
that enhanced expression of the DFNA5-encoding mRNA
increases the cellular susceptibility to drug-induced apoptosis
in malignant melanoma cells, further evidence is provided that
DFNA5 may indeed be involved in cancer biology and that
the status of the DFNA5 mRNA expression level could lead
to consequences in therapeutic strategies.
Analyses of the expression pattern of DFNA5-encoding
mRNA in various human tissues revealed a high expression
level in the placenta while no or very low expression could be
detected in other tissues [10,11]. Moreover, in embryonic cell
lines, breast cancer cell lines, carcinoma lines derived from
human tissue other than breast, including melanoma lines
[8], and various primary human breast tumor specimens, tran-
scription of the DFNA5-encoding gene could be detected.
These data indicate that DFNA5 mRNA expression is partic-
ularly pronounced in embryonic, fetal and cancerous cells.
Especially in these cell types the regulation, or in the case of
cancer cells the dysregulation of di¡erentiation and develop-
ment by many factors involved in the control of programmed
cell death is of prominent importance. Thus, a putative activ-
ity of DFNA5 in the in£uence of apoptotic cell death appears
not to be astonishing.
The exact molecular events by which the DFNA5-mediated
alterations in etoposide susceptibility are e¡ected are not
clear. However, it could be demonstrated that the enhanced
drug sensitivity of DFNA5 cDNA-transfected melanoma
clones is accompanied by an increased cellular disposition
for programmed cell death mediated by activation of cas-
pase-3 following etoposide exposure. This observation gives
evidence that the product encoded by the DFNA5 gene might
be involved in a cellular pathway leading to apoptosis. This
pathway should be triggered by drug treatment or alternative
cellular stress. Thus, a reduced expression level of the
DFNA5-encoding transcript would cause a decrease of apo-
ptotic events which would manifest themselves as an increase
in drug tolerance.
The available data did not explicitly clarify whether the
DFNA5 gene product has a direct e¡ect on apoptosis in mel-
anoma cells. Hence, it should be taken into consideration that
the DFNA5-dependent cellular events involved in triggering
programmed cell death might be mediated indirectly, e.g. by a
DFNA5-dependent modulation of alternative drug resistance
mechanisms being active in the etoposide-resistant melanoma
cells. At least it was demonstrated that the DNA mismatch
repair system, which is modulated in the etoposide-resistant
melanoma cells [4,5], plays an important role in antineoplastic
drug resistance by a¡ecting cellular pathways leading to apo-
ptosis (overview in [17]).
The 30^35% extent of change in drug susceptibility in this
cellular in vitro model is not dramatic. However, a di¡erent
result is not to be expected since it was demonstrated that
alternative mechanisms such as alterations in DNA mismatch
repair [4,5] and DNA topoisomerase II activity [6] were asso-
ciated with the acquired etoposide resistance phenotype ex-
hibited by MeWo ETO 1 cells. Furthermore, additional can-
didate factors were identi¢ed [8] which might play a potential
role in the etoposide resistance phenotype of these cells. On
the other hand, it is important to note that the e¡ect of
change in drug tolerance associated with alterations in
DFNA5 mRNA expression level has implications and is of
clinical signi¢cance. In the clinical situation, a two-fold in-
crease in drug resistance is su⁄cient to circumvent a success-
ful chemotherapeutic treatment of malignant cells. Thus, for
the oncologist it is critical to take into consideration that
changes in DFNA5 mRNA expression level may be involved
in a multimodal mechanism leading to therapy resistance of
malignant melanoma.
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